# A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

> **NCT02182440** · PHASE2 · COMPLETED · sponsor: **AM-Pharma** · enrollment: 301 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **BIOLOGICAL:** recAP
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02182440
- **Lead sponsor:** AM-Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-18
- **Primary completion:** 2017-05-25
- **Final completion:** 2017-09-27
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2020-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182440, "A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02182440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*